Monday, February 20, 2017 5:00:10 PM
Theralase Extends Research Agreement with University Health Network
April 28, 2016, Theralase Technologies Inc., a leading biotech company focused on commercialization of medical devices to eliminate pain and development of Photo Dynamic Compounds (“PDCs”) to destroy cancer, announced today that it has extended its Sponsored Research Agreement (“SRA”) with University Health Network (“UHN”), one of the top 5 cancer research institutes in the world.
Under the terms of the SRA, Theralase and UHN will work together to evaluate Theralase’s patented and patent pending platform of novel Ruthenium (“Ru”) and Osmium (“Os”) based PDCs for new cancer indications, including: lung, melanoma and brain cancer.
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM